Temporal effects of Palmitoylethanolamide (PEA) in modulating knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Dose used in the study
- Two dose levels of palmitoylethanolamide against placebo. The record checked does not give the doses or the number of participants.
- Duration
- 12 weeks
- What was measured
- Change in the WOMAC osteoarthritis index total score at week 12 as the main measure; WOMAC subscales, PROMIS-29 scores and OMERACT-OARSI responder rates as secondary measures
What the authors reported
This trial found:
- Placebo showed the greater improvement at week 4, while the palmitoylethanolamide groups showed larger falls over the following 8 weeks (low dose −16.05, high dose −15.43, versus −11.76 with placebo).
- Differences in WOMAC scores were not statistically significant (p > 0.05).
- The high-dose group had a higher responder rate than placebo at week 12 in a post-hoc analysis (p = 0.034).
- The supplement was well tolerated.
Limits of this study
The main outcome did not differ significantly from placebo. The positive finding is a post-hoc responder analysis in one dose group. The entry was checked against the abstract only, and the record did not give participant numbers, doses or funding.
Source
PubMed 42635976 · doi:10.1177/10538127261477951
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.